Climb Financial Statements From 2010 to 2024

CLYM Stock   2.10  0.17  7.49%   
Climb Bio financial statements provide useful quarterly and yearly information to potential Climb Bio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Climb Bio financial statements helps investors assess Climb Bio's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Climb Bio's valuation are summarized below:
There are over twenty-three available fundamental signals for Climb Bio, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Climb Bio's prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Climb Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Climb Bio's main balance sheet or income statement drivers, such as Selling General Administrative of 16.1 M, Total Revenue of 0.0 or Research Development of 20.4 M, as well as many indicators such as . Climb financial statements analysis is a perfect complement when working with Climb Bio Valuation or Volatility modules.
  
Check out the analysis of Climb Bio Correlation against competitors.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.

Climb Bio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets121.9 M110.5 M54.1 M
Slightly volatile
Other Current Liabilities118 K124.2 K438.6 K
Slightly volatile
Total Current Liabilities3.6 M2.8 M3.5 M
Slightly volatile
Total Stockholder Equity116.9 M107.6 M50.5 M
Slightly volatile
Accounts Payable62.7 K66 K948.6 K
Slightly volatile
Cash56.1 M93.1 M31 M
Slightly volatile
Non Current Assets Total203.3 K214 K3.7 M
Pretty Stable
Non Currrent Assets Other14.2 K15 K1.9 M
Slightly volatile
Common Stock Shares Outstanding28.6 M27.7 M24.5 M
Slightly volatile
Other Current Assets556.7 K586 K341.4 K
Slightly volatile
Total Liabilities3.6 M2.9 M3.5 M
Slightly volatile
Total Current Assets114.1 M110.3 M49.9 M
Slightly volatile
Capital Stock2.6 K2.7 K34.1 M
Slightly volatile
Net Working Capital109.1 M107.4 M46.4 M
Slightly volatile
Non Current Liabilities Other15.9 K25.3 K9.8 K
Slightly volatile

Climb Bio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative16.1 M24.9 M6.6 M
Slightly volatile
Research Development20.4 M15.4 M12.5 M
Slightly volatile
Total Operating Expenses36.5 M40.3 M19.1 M
Slightly volatile
Net Interest Income3.3 M4.6 M1.7 M
Slightly volatile
Interest Income3.3 M4.6 M1.7 M
Slightly volatile

Climb Fundamental Market Drivers

Short Term Investments13.7 M

About Climb Bio Financial Statements

Climb Bio investors utilize fundamental indicators, such as revenue or net income, to predict how Climb Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Climb Bio is a strong investment it is important to analyze Climb Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Climb Bio's future performance. For an informed investment choice regarding Climb Stock, refer to the following important reports:
Check out the analysis of Climb Bio Correlation against competitors.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.